SCHEMBL2832686

SCHEMBL2832686

COc1cc(C)c(S(=O)(=O)N2CCC[C@H]2COc2ccnc(N3CCC(OCCN4CCCC4)(c4cccnc4)CC3)n2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 13/20 0.38
CASP7 P55210 12/20 0.38
CASP6 P55212 5/20 0.35
CASP1 P29466 1/20 0.35
NAMPT P43490 1/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
CHRNA1 P02708 1/20 0.33
CHRNB1 P11230 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33
CHRNA4 P43681 1/20 0.33
CHRNB3 Q05901 1/20 0.33
HTR7 P34969 2/20 0.32
TMEM97 Q5BJF2 1/20 0.32
SIGMAR1 Q99720 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835287 0.99 CASP3 (0.36) CASP3CASP7CASP6CASP1NAMPT
SCHEMBL2833663 0.91 HTR7 (0.33) CASP3CASP7HTR7TMEM97SIGMAR1
SCHEMBL2836739 0.87 CASP3 (0.37) CASP3CASP7CASP6CASP1NAMPT
SCHEMBL2832697 0.87 CASP3 (0.38) CASP3CASP7CASP6CASP1NAMPT
SCHEMBL2836096 0.87 LMNA (0.41) CASP3CASP7CASP6CASP1NAMPT
SCHEMBL2839171 0.86 LMNA (0.41) CASP3CASP7CASP6CASP1NAMPT
SCHEMBL2835468 0.83 BDKRB1 (0.38) DRD2DRD3CHRNB2CHRNA4
SCHEMBL3441702 0.82 BDKRB1 (0.40) CASP3CASP7NAMPTDRD2DRD3
SCHEMBL3441720 0.82 BDKRB1 (0.40) CASP3CASP7NAMPTDRD2DRD3
SCHEMBL2835296 0.82 HTR7 (0.40) CASP3CASP7DRD2DRD3HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS CASP3 1252/4885CASP7 1641/4885CASP6 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.